Cargando…

Prognostic significance of the neutrophil/lymphocyte ratio in patients undergoing treatment with nivolumab for recurrent non-small-cell lung cancer

AIM: We investigated the prognostic potential of pretherapy measurement of the neutrophil/lymphocyte ratio (NLR) in patients (n = 56) with non-small-cell lung cancer deemed suitable for treatment with nivolumab. MATERIALS & METHODS: This was a multicenter, noninterventional, retrospective data a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rapoport, Bernardo L, Theron, Annette J, Vorobiof, Daniel A, Langenhoven, Lizanne, Hall, Jacqueline M, Van Eeden, Ronwyn I, Smit, Teresa, Chan, Sze-Wai, Botha, Michael C, Raats, Johann I, Necker, Margriet De, Anderson, Ronald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399612/ https://www.ncbi.nlm.nih.gov/pubmed/32774468 http://dx.doi.org/10.2217/lmt-2020-0014

Ejemplares similares

Tuberculosis Infection in a Patient Treated With Nivolumab for Non-small Cell Lung Cancer: Case Report and Literature Review
por: van Eeden, Ronwyn, et al.
Publicado: (2019)

Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study
por: Rapoport, Bernardo Leon, et al.
Publicado: (2018)

Role of the Neutrophil in the Pathogenesis of Advanced Cancer and Impaired Responsiveness to Therapy†
por: Rapoport, Bernardo L., et al.
Publicado: (2020)

Phenotype and Treatment of Breast Cancer in HIV-Positive and -Negative Women in Cape Town, South Africa
por: Langenhoven, Lizanne, et al.
Publicado: (2016)

Ipilimumab in Pretreated Patients With Advanced Malignant Melanoma: Results of the South African Expanded-Access Program
por: Rapoport, Bernardo L., et al.
Publicado: (2016)

Dupuytren’s contractures associated with the BRAF inhibitor vemurafenib: a case report
por: Chan, Sze Wai, et al.
Publicado: (2015)

Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells
por: Anderson, Ronald, et al.
Publicado: (2019)

High Mobility Group Box 1 in Human Cancer
por: Rapoport, Bernardo L., et al.
Publicado: (2020)

Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor–Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint
por: Myburgh, Ettienne J., et al.
Publicado: (2016)

Effects of Moxifloxacin on Human Neutrophil and T-Lymphocyte Functions in Vitro
por: Potjo, Moliehi, et al.
Publicado: (2010)

Contrasting Immunopathogenic and Therapeutic Roles of Granulocyte Colony-Stimulating Factor in Cancer
por: Theron, Annette J., et al.
Publicado: (2020)

Pro-Tumorigenic and Thrombotic Activities of Platelets in Lung Cancer
por: Anderson, Ronald, et al.
Publicado: (2023)

Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer
por: Gannichida, Ako, et al.
Publicado: (2022)

Neutrophil 'connectivity': key to neutrophil-mediated tissue injury?
por: Mahmudi-Azer, Salahaddin, et al.
Publicado: (2003)

Systemic Immune Dysregulation in Early Breast Cancer Is Associated With Decreased Plasma Levels of Both Soluble Co-Inhibitory and Co-Stimulatory Immune Checkpoint Molecules
por: Rapoport, Bernardo L., et al.
Publicado: (2022)

Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3
por: Rapoport, Bernardo L., et al.
Publicado: (2023)

Interactions of HIV and Antiretroviral Therapy With Neutrophils and Platelets
por: Madzime, Morris, et al.
Publicado: (2021)

Comparison of the effects of electronic cigarette vapours and tobacco smoke extracts on human neutrophils in vitro
por: Richards, Guy A., et al.
Publicado: (2023)

Frontiers in Pharmacology: Review Manuscript Targeting of the Neutrophil as an Adjunctive Strategy in Non-Small Cell Lung Cancer
por: Anderson, Ronald, et al.
Publicado: (2021)

Formoterol is more effective than salmeterol in suppressing neutrophil reactivity
por: Tintinger, Gregory R., et al.
Publicado: (2015)

Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
por: Nakaya, Aya, et al.
Publicado: (2018)

Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study
por: Ogata, Takatsugu, et al.
Publicado: (2018)

Chronological Changes in Neutrophil/lymphocyte Ratio in Advanced Gastric Cancer Patients Treated with Nivolumab: a Report of Nine Cases
por: Nakamura, Naohiko, et al.
Publicado: (2020)

Cigarette smoke condensate attenuates phorbol ester-mediated neutrophil extracellular trap formation
por: Bokaba, Refilwe Philadelphia, et al.
Publicado: (2017)

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma
por: Tucker, Matthew D., et al.
Publicado: (2021)

Pharmacological control of neutrophil-mediated inflammation: Strategies targeting calcium handling by activated polymorphonuclear leukocytes
por: Tintinger, Gregory R, et al.
Publicado: (2009)

Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
por: Capone, Mariaelena, et al.
Publicado: (2018)

PD-L1(+) neutrophils as novel biomarkers for stage IV melanoma patients treated with nivolumab
por: Cristinziano, Leonardo, et al.
Publicado: (2022)

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
por: Lai, Gillianne G.Y., et al.
Publicado: (2022)

Pro-Inflammatory Interactions of Dolutegravir with Human Neutrophils in an In Vitro Study
por: Theron, Annette J., et al.
Publicado: (2022)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Neutrophil‐to‐lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non‐small‐cell lung cancer
por: Takeda, Takayuki, et al.
Publicado: (2018)

Recent advances in the medical treatment of breast cancer
por: Vorobiof, Daniel A.
Publicado: (2016)

The Beta-2-Adrenoreceptor Agonists, Formoterol and Indacaterol, but Not Salbutamol, Effectively Suppress the Reactivity of Human Neutrophils In Vitro
por: Anderson, Ronald, et al.
Publicado: (2014)

Chest CT Cinematic Rendering of SARS-CoV-2 Pneumonia
por: Necker, Fabian N., et al.
Publicado: (2021)

Ranging behaviour and habitat preferences of the Martial Eagle: Implications for the conservation of a declining apex predator
por: van Eeden, Rowen, et al.
Publicado: (2017)

Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers
por: Dusselier, Matthieu, et al.
Publicado: (2019)

A Case Report of Steroid Responsive Nivolumab-Induced Encephalitis
por: Richard, Kaja, et al.
Publicado: (2017)

Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016)

Focus on Nivolumab in NSCLC
por: Cortinovis, Diego L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kgn99335a2ql36854t9kprieo7